Granza Bio
Building programmable therapeutics for the immune system
About Granza Bio
Granza Bio is developing programmable therapeutics for the immune system. Our platform is built on the foundational discovery of immune “superkiller” attack particles — the natural ammunition used by cytotoxic immune cells to deliver potent, localized killing. By re-arming exhausted immune cells with newly programmed ammunition, Granza restores and enhances immune function. This approach enables a new class of treatments with the potential to transform diseases ranging from cancer to autoimmunity.
Company details
Funding
Total raised
$7.6M
Last stage
Seed
Investors
Founders
Ashwin Jainarayanan
Granza Bio, DPhil (PhD) in Interdisciplinary Bioscience - University of Oxford
LinkedIn
Ashwin Menon Nandakumar
PhD in Oncology from the University of Oxford; previously set up clinical trials and brings oncology start-up experience; Cancer Research UK post-doctoral researcher at Oxford and ICR London.
LinkedInMichael Dustin
Professor of Molecular Immunology at the University of Oxford; Director of Research at the Kennedy Institute of Rheumatology; discoverer of immune attack particles (SMAPs).
What happens next.
No applications, no recruiter spam. Just the intro.
Confirm the fit
A few questions to make sure this role is the right shape for you. Two minutes.
I pitch you to the company
I write the intro, send it to the founder, and handle the back-and-forth.
A meeting lands on your calendar
If they’re a yes, I book the chat. You show up — that’s the whole job-hunt.